{"id":"clobetasol-propionate-0-05-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Folliculitis"},{"rate":null,"effect":"Hypertrichosis"},{"rate":null,"effect":"Acneiform eruptions"},{"rate":null,"effect":"Hypopigmentation"},{"rate":null,"effect":"Perioral dermatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clobetasol propionate is a Class I (super-potent) corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory cytokines, reduced immune cell infiltration, and suppression of local inflammatory cascades. The foam formulation provides enhanced penetration and coverage for scalp and body surface conditions. It is indicated for short-term treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.","oneSentence":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:50.892Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body)"},{"name":"Psoriasis"},{"name":"Eczema"},{"name":"Lichen planus"},{"name":"Other steroid-responsive dermatologic conditions"}]},"trialDetails":[{"nctId":"NCT00436540","phase":"PHASE4","title":"A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-03","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT00803439","phase":"","title":"Randomized Study to Compare the Bioavailability of Two Clobetasol Propionate 0.05% Topical Foams","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2005-04","conditions":"Healthy","enrollment":80},{"nctId":"NCT00438399","phase":"PHASE3","title":"Subject Preference for Scalp Psoriasis Treatment","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2007-02","conditions":"Scalp Psoriasis","enrollment":219},{"nctId":"NCT01235442","phase":"PHASE3","title":"Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09","conditions":"Psoriasis","enrollment":592},{"nctId":"NCT01323673","phase":"PHASE4","title":"Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-11-15","conditions":"Dermatitis, Chronic","enrollment":125},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36},{"nctId":"NCT01745133","phase":"PHASE4","title":"Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis","status":"COMPLETED","sponsor":"Leon Kircik, M.D.","startDate":"2013-01","conditions":"Psoriasis","enrollment":63},{"nctId":"NCT00852761","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-03","conditions":"Plaque-Type Psoriasis","enrollment":34},{"nctId":"NCT01111981","phase":"PHASE4","title":"Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia","status":"UNKNOWN","sponsor":"Callender Center for Clinical Research","startDate":"2009-10","conditions":"Alopecia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Olux® Foam"],"phase":"marketed","status":"active","brandName":"Clobetasol Propionate 0.05% Foam","genericName":"Clobetasol Propionate 0.05% Foam","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobetasol propionate is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (scalp and body), Psoriasis, Eczema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}